Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OPGN

OPGN - OpGen Inc Stock Price, Fair Value and News

$25.00+0.25 (+1.01%)
Market Closed

17/100

OPGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

17/100

OPGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OPGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OPGN Price Action

Last 7 days

1.0%

Last 30 days

3.1%

Last 90 days

135.7%

Trailing 12 Months

2400%

OPGN RSI Chart

OPGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OPGN Valuation

Market Cap

249.3M

Price/Earnings (Trailing)

36.43

Price/Sales (Trailing)

32.37

EV/EBITDA

34.48

Price/Free Cashflow

-205.85

OPGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OPGN Fundamentals

OPGN Revenue

Revenue (TTM)

5.2M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

OPGN Earnings

Earnings (TTM)

6.8M

Earnings Growth (Yr)

-106.82%

Earnings Growth (Qtr)

-117.34%

OPGN Profitability

EBT Margin

135.10%

Return on Equity

67.37%

Return on Assets

54.14%

Free Cashflow Yield

-0.49%

OPGN Investor Care

Shares Dilution (1Y)

0.03%

Diluted EPS (TTM)

1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20242.7M2.0M3.6M5.2M
20233.1M2.8M3.1M3.4M
20223.9M4.1M3.3M2.6M
20214.4M4.1M4.2M4.3M
20203.1M3.3M3.7M4.2M
20193.1M3.3M3.4M3.5M
20183.3M3.4M3.2M2.9M
20173.7M3.2M3.2M3.2M
20163.8M4.6M4.3M4.0M
20153.5M2.8M3.0M3.2M
20140004.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About OpGen Inc

OPGN
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEopgen.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES85

OpGen Inc Frequently Asked Questions

OPGN is the stock ticker symbol of OpGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Mar 12 2026, market cap of OpGen Inc is 249.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Mar 12 2026, OPGN's PE ratio (Price to Earnings) is 36.43 and Price to Sales (PS) ratio is 32.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPGN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, OpGen Inc has provided -0.586 (multiply by 100 for percentage) rate of return.